Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amb a 1 Immunostimulatory Conjugate
- Development stage
- Unknown
- Lead developer
- Dynavax Technologies
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Amb a 1 Immunostimulatory Conjugate (AIC) is an investigational immunotherapeutic developed by Johns Hopkins University in collaboration with Dynavax Technologies for the treatment of seasonal allergic rhinitis caused by ragweed allergy. The drug consists of the purified major ragweed allergen, Amb a 1, covalently linked to immunostimulatory phosphorothioate oligodeoxynucleotides (ISS-ODN) containing unmethylated CpG motifs. AIC functions by targeting the immune system's Toll-like receptor 9 (TLR9), which promotes a Th1-biased immune response and suppresses the Th2-mediated allergic response typical of ragweed allergy. This shift in the immune profile leads to reduced nasal inflammation, decreased eosinophilia, and improved clinical symptoms during ragweed season. It is typically administered via a short course of subcutaneous injections prior to the onset of the allergy season.
- Other names
- Amb a 1-ISSAmb a 1-ISS conjugateRagweed-ISS conjugateDynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate
02
Targets
Amb a 1FCER1 (Fc epsilon RI receptor)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on Amb a 1 Immunostimulatory Conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amb a 1 Immunostimulatory Conjugate.